These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37556427)

  • 1. Synthesis of
    Deiser S; Drexler M; Moreno-Alcántar G; Irl M; Schmidt C; Günther T; Casini A
    Inorg Chem; 2023 Dec; 62(50):20710-20720. PubMed ID: 37556427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
    Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
    Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3p-C-NETA: A versatile and effective chelator for development of Al
    Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
    Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of patient doses of (177)Lu-DOTA-TATE using indigenously produced (177)Lu: the Indian experience.
    Das T; Chakraborty S; Kallur KG; Venkatesh M; Banerjee S
    Cancer Biother Radiopharm; 2011 Jun; 26(3):395-400. PubMed ID: 21728843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, preparation and biological evaluation of a
    Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
    Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals.
    Müller C; Farkas R; Borgna F; Schmid RM; Benešová M; Schibli R
    Bioconjug Chem; 2017 Sep; 28(9):2372-2383. PubMed ID: 28898054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro evaluation of
    Zhang J; Wang Z; Liu H; Cai L; Feng Y; Zhou L; Wei H; Xie Y; Chen Y
    Hell J Nucl Med; 2019; 22(2):103-110. PubMed ID: 31273351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
    Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.).
    Hosono M; Ikebuchi H; Nakamura Y; Nakamura N; Yamada T; Yanagida S; Kitaoka A; Kojima K; Sugano H; Kinuya S; Inoue T; Hatazawa J
    Ann Nucl Med; 2018 Apr; 32(3):217-235. PubMed ID: 29333565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
    Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
    Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
    Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.
    Lewis JS; Wang M; Laforest R; Wang F; Erion JL; Bugaj JE; Srinivasan A; Anderson CJ
    Int J Cancer; 2001 Dec; 94(6):873-7. PubMed ID: 11745491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development and validation of a high performance liquid chromatography method to determine the radiochemical purity of [
    van Andel L; Aalbersberg EA; Geluk-Jonker MM; Stokkel MPM; Beijnen JH; Hendrikx JJMA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 May; 1171():122605. PubMed ID: 33740691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
    Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
    Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Sinnes JP; Bauder-Wüst U; Schäfer M; Moon ES; Kopka K; Rösch F
    EJNMMI Radiopharm Chem; 2020 Nov; 5(1):28. PubMed ID: 33242189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia.
    Balkin ER; Liu D; Jia F; Ruthengael VC; Shaffer SM; Miller WH; Lewis MR
    Nucl Med Biol; 2014 Jan; 41(1):36-42. PubMed ID: 24267052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter,
    Shalgunov V; Engudar G; Bohrmann L; Wharton L; Maskell K; Johann K; Barz M; Schaffer P; Herth MM; Radchenko V
    Nucl Med Biol; 2022; 104-105():11-21. PubMed ID: 34839209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
    Jiang L; Miao Z; Kimura RH; Liu H; Cochran JR; Culter CS; Bao A; Li P; Cheng Z
    Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):613-22. PubMed ID: 21153409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.